SCHOTT Pharma with robust first half of the year and strong cash flow

Segments

Sales in the Drug Containment Solutions (DCS) segment, which includes glass vials, ampoules and cartridges for the storage of injectable drugs, rose to EUR 286.4 million. This corresponds to an increase of 8.3% at constant currencies (reported: 5.7%). This was driven by continued high demand for sterile cartridges and vials as well as specialty vials. HVS in this segment continued to develop very positively, accounting for 25% of revenue (H1 2025: 20%). EBITDA grew disproportionately by 17.2% to EUR 71.8 million due to favorable volume and product mix effects. The EBITDA margin was 25.1%, compared to 22.6% in the first half of 2025.

The Drug Delivery Systems (DDS) segment consists of glass and polymer syringes and thus solely of HVS. With revenue of EUR 201.8 million, it was -5.4% below the first half of 2025 at constant currencies (reported: - 4.9%). This was due to a lower demand for polymer syringes caused by declining mRNA vaccinations, which could not be fully compensated for by the continued high demand for prefillable glass syringes, especially for GLP-1 therapies. Lower production capacity utilization for polymer syringes and a one-off impairment loss on customer-specific glass syringes in the high single-digit million range led to a decline in earnings in DDS. The segment's EBITDA fell by 18.0% to EUR 59.5 million. The EBITDA margin was 29.5%. Adjusted for the one-off impairment effect, the margin would have been only slightly below the previous year's figure of 34.2%.

Cashflow and investments

Cash flow from operating activities totaled EUR 95.1 million, which is EUR 22.5 million more than in the previous year. Free cash flow reached EUR 45.4 million, mainly as a result of improved receivables management, more than doubling the previous year's figure.

SCHOTT Pharma continued to expand its capacities in both segments, especially for HVS, in the first half of 2026. The focus was on manufacturing sites in Switzerland and Hungary to meet the continuing increase in demand for specialized drug containment solutions. Capital expenditures (CAPEX) of EUR 50.1 million were roughly in line with the EUR 51.0 million recorded in the same period of the previous year.

Innovations

In April 2026, SCHOTT Pharma announced that it would launch the new cartriQ® BioPure towards the end of 2026. The glass cartridge is equipped with special product properties for the storage and administration of complex biologics and can be integrated into self-administration systems. The product thus addresses important pharmaceutical trends and further complements the company's portfolio of innovative HVS.

Outlook

SCHOTT Pharma confirms the forecast published in December for the 2026 financial year, according to which the company expects revenue growth at constant currencies of 2–5% and an EBITDA margin of around 27%.

The key figures for Q2 and H1 can be found here.

For additional news about SCHOTT Pharma, please visit our media center.

Webcast

Christian Mias (CEO) and Reinhard Mayer (CFO) will present the results for the second quarter and first half of 2026 during a conference call for analysts and investors on May 13, 2026, at 11:00 a.m. CEST. The audio webcast can be followed via the following link. The accompanying presentation is available on our IR website.

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 986 million in the fiscal year 2025. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Further information at www.schott-pharma.com